Related Experiment Videos
Antineoplastic drug monitoring
1Harvard Medical School, Boston, Massachusetts.
Clinics in Laboratory Medicine
|September 1, 1987
Abstract:
The ability to monitor biologically significant levels of antineoplastic drugs in patients' plasma is rapidly expanding. The expanded application of therapeutic drug monitoring to the clinical practice of oncology will require a better understanding of the relationship between drug levels, toxicity, and therapeutic benefit in particular patient populations.
Insights
Monitoring antineoplastic drug levels in patients is expanding. Understanding drug levels, toxicity, and benefits is crucial for oncology practice.
Area of Science:
- Pharmacology
- Clinical Oncology
- Drug Monitoring
Background:
- Therapeutic drug monitoring (TDM) for antineoplastic agents is becoming more prevalent.
- Accurate measurement of drug concentrations in patient plasma is essential.
Purpose of the Study:
- To highlight the expanding capabilities in monitoring antineoplastic drug levels.
- To emphasize the need for understanding the correlation between drug concentrations and clinical outcomes.
Main Methods:
- This study focuses on the implications of increased TDM in oncology.
- It reviews the current landscape of antineoplastic drug monitoring techniques.
Main Results:
- The capacity to measure biologically significant antineoplastic drug levels is growing.
- This expansion necessitates further research into drug efficacy and safety.
Conclusions:
- Widespread application of TDM in oncology requires a deeper understanding of drug level-toxicity-benefit relationships.
- Further investigation is needed to optimize patient populations for TDM.